Adding vaborbactam significantly reduces the MIC of meropenem alone in KPC-producing strains of Enterobacteriaceae1*
Common adverse reactions for VABOMERE in the TANGO I trial were consistent with those reported for meropenem alone2-4
VABOMERE demonstrated in vitro activity against Enterobacteriaceae in the presence of a number of β-lactamases and ESBLs of the KPC, SME, TEM, SHV, CTX-M, CMY, and ACT groups2*
98.4% with VABOMERE vs 94.3% with piperacillin/tazobactam1,2
*In vitro activity does not necessarily correlate with clinical efficacy.
†Composite of both a clinical outcome of cure or improvement and a microbiologic outcome of eradication.2
*ESBL=extended spectrum ß-lactamase.
ESBL-producing Enterobacteriaceae pose a serious threat8:
deaths per year
Account for $40,000
in excess medical costs
per each infection per year
*National trend based on BD Insights Research Database.
A multicenter, large-scale retrospective data set of electronically captured microbiology and susceptibility results from 192 facilities that consecutively reported data during 2011 and 2017. The data set was stored in the BD Insights Research Database (Becton, Dickinson, and Company, Franklin Lakes, NJ). Nonduplicate isolates† from urine, intra-abdominal, respiratory, skin, blood, and “other” sources from inpatients who had susceptibility results for Enterobacteriaceae were included.
Daisy, 70 yr
cUTI with a history of
significant bacterial infections
and recent broad-spectrum
cUTI with a history of significant bacterial infections and recent broad-spectrum antibiotics exposure
Jackson, 75 yr
cUTI post-radical prostatectomy and indwelling catheter
Steve, 61 yr
cUTI in a patient with a
history of chronic
lymphocytic leukemia (CLL)
and multiple hospitalizations
cUTI in a patient with a history of chronic lymphocytic leukemia (CLL) and multiple hospitalizations
These hypothetical case studies are meant to be illustrative. They are not intended to offer medical advice. Determination of
appropriate treatment is at the discretion of the physician. Treatment results may vary by patient.
References: 1. Data on file: Melinta Therapeutics, Inc. 2. VABOMERE [package insert]: Melinta Therapeutics, Inc. 3. Merrem I.V. [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014. 4. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: The TANGO I randomized clinical trial. JAMA. 2018;319(8):788-799. doi: 10.1001/
VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.
The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.Please see full Prescribing Information.